Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP trimmed its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO) by 17.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,085,281 shares of the company’s stock after selling 223,603 shares during the quarter. Dimensional Fund Advisors LP owned 1.33% of Sutro Biopharma worth $3,180,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. lifted its position in Sutro Biopharma by 214.3% during the first quarter. Jacobs Levy Equity Management Inc. now owns 1,069,522 shares of the company’s stock worth $6,043,000 after buying an additional 729,239 shares during the period. Acadian Asset Management LLC lifted its position in Sutro Biopharma by 30.8% in the 2nd quarter. Acadian Asset Management LLC now owns 1,574,958 shares of the company’s stock valued at $4,613,000 after purchasing an additional 370,705 shares during the last quarter. Opaleye Management Inc. acquired a new position in Sutro Biopharma during the 4th quarter worth $1,293,000. Vanguard Group Inc. grew its position in Sutro Biopharma by 4.6% in the 1st quarter. Vanguard Group Inc. now owns 3,022,790 shares of the company’s stock valued at $17,079,000 after buying an additional 132,790 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Sutro Biopharma in the 1st quarter worth $714,000. Institutional investors and hedge funds own 96.99% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on STRO shares. Truist Financial reduced their price target on shares of Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, August 16th. JMP Securities reaffirmed a “market outperform” rating and issued a $17.00 price target on shares of Sutro Biopharma in a research report on Monday, September 16th. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Sutro Biopharma in a research note on Monday, September 16th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $12.13.

Sutro Biopharma Trading Down 4.3 %

Shares of Sutro Biopharma stock opened at $3.31 on Friday. The company has a market cap of $270.74 million, a P/E ratio of -1.76 and a beta of 1.17. Sutro Biopharma, Inc. has a 1-year low of $2.01 and a 1-year high of $6.13. The business has a 50-day moving average price of $3.94 and a two-hundred day moving average price of $3.93.

Sutro Biopharma (NASDAQ:STRO) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.20. The business had revenue of $25.71 million during the quarter, compared to analyst estimates of $26.28 million. Sutro Biopharma had a negative return on equity of 102.06% and a negative net margin of 73.48%. Equities research analysts forecast that Sutro Biopharma, Inc. will post -2.96 EPS for the current fiscal year.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.